SPINK12 Inhibitors
SPINK12 inhibitors encompass a diverse range of chemical compounds that indirectly decrease the functional activity of SPINK12 by targeting specific signaling pathways or biological processes. Afatinib and Gefitinib, both EGFR inhibitors, contribute to the downregulation of SPINK12 by hindering EGFR signaling, which is pivotal in the proliferation and differentiation of epithelial tissues that express SPINK12. Similarly, Dasatinib, by inhibiting Src kinase, disrupts upstream signaling pathways that could regulate SPINK12 expression, while Imatinib's inhibition of the BCR-ABL tyrosine kinase may also lead to the decreased expression of SPINK12 by affecting related cell proliferation and survival pathways. The action of Palbociclib, a CDK4/6 inhibitor, impedes cell cycle progression, potentially leading to reduced SPINK12 expression in proliferating cells. Likewise, Trametinib and U0126, both targeting MEK, downregulate SPINK12 indirectly by inhibiting the MAPK/ERK pathway, thereby influencing processes where SPINK12 is involved.
Further expanding the repertoire of SPINK12 inhibitors, Sorafenib's multi-kinase inhibition, including the RAS/RAF/MEK/ERK pathway, may decrease SPINK12 expression by altering the signaling that mediates its regulation. Rapamycin and Temsirolimus, as mTOR inhibitors, contribute to the reduction of SPINK12 expression by dampening cellular growth signals. LY294002's inhibition of PI3K leads to the downregulation of SPINK12 by suppressing the AKT signaling pathway which is critical for cellular survival and growth.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $112.00 $194.00 | 13 | |
Afatinib is an EGFR inhibitor, and by blocking EGFR, it can lead to the downregulation of SPINK12 as EGFR signaling is involved in the proliferation and differentiation of epithelial tissues where SPINK12 is expressed. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src kinase inhibitor. Src kinase is upstream of various signaling pathways that may regulate the expression of SPINK12, inhibiting its expression by hindering signal transduction. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib, a CDK4/6 inhibitor, disrupts the cell cycle, which could indirectly lead to decreased expression of SPINK12 by halting cell proliferation where SPINK12 might be expressed. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor, which could reduce the expression of SPINK12 indirectly by inhibiting the MAPK/ERK pathway, affecting cellular processes that involve SPINK12. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets various kinases, including those in the RAS/RAF/MEK/ERK pathway, which may lead to reduced expression of SPINK12 by altering the signaling that regulates its expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is involved in cell growth and proliferation. By inhibiting mTOR, Rapamycin can indirectly decrease the expression of SPINK12 by reducing cellular growth signals. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
Nutlin-3 disrupts the interaction between p53 and MDM2, leading to the activation of p53 and potential downregulation of SPINK12, as p53 can regulate the expression of numerous genes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits the BCR-ABL tyrosine kinase, and through this inhibition, it could lead to decreased expression of SPINK12 by affecting signaling pathways that regulate cell proliferation and survival. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which could lead to decreased SPINK12 expression by inhibiting the AKT signaling pathway, affecting survival and growth signals. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which may lead to decreased expression of SPINK12 by inhibiting the MAPK/ERK signaling pathway, affecting cellular differentiation processes. | ||||||